Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
ConditionBladder Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChinese University of Hong Kong
About this trial
This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.
Eligibility criteria
Qualifiers
Age 18 years or above
Recurrent bladder tumour
Multiple bladder tumours
Any bladder tumour size of >1cm
Disqualifiers
EAU low-risk NIMBC as intravesical BCG therapy should not be offered (5)
EAU very high-risk NMIBC as upfront radical cystectomy should be offered (5)
Any prior use of intravesical BCG therapy
Presence or prior history of upper urinary tract malignancy
Trial design
Treatments tested in this trial
- Conventional Transurethral Resection of Bladder Tumour
- Transurethral En Bloc Resection of Bladder Tumour
Treatment groups
732 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov